"The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.
HER2 is a protein involved in normal cell growth. It is foun"...
PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.
Last reviewed on RxList: 4/7/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Perjeta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.